hmmm, so after checking their site, it looks like they posted 3 updates yesterday, all relating to the "building blocks" that were utilized in the study that was published in Nature.com (link back). These "building blocks" were used to produce a new variation of a chemotherapeutic drug that, compared to the previous version, "led to increased therapeutic activity of the drug in vivo" by having "induced tumor regression". In addition, the new variation (NT4-paclitaxel) "...is very hydrophilic, which may improve its pharmacokinetic profile and allow the use of less toxic dilution buffers, further decreasing its general chemotherapic toxicity."
News 
Market Data 
Discover 
